11th Annual Meeting of the EBMT 1985
DOI: 10.1007/978-3-662-40457-7_83
|View full text |Cite
|
Sign up to set email alerts
|

Immunisation Against Hepatitis B in BMT- and Leukemia-Patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
7
0

Year Published

1993
1993
2005
2005

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(7 citation statements)
references
References 0 publications
0
7
0
Order By: Relevance
“…3,6 Attempts at active immunization against HBV in the immediate pre-and post-BMT period were unsuccessful, probably due to inefficient T cell-dependent B cell responses, which may last for about a year following BMT. 10,11 Failure of effective immunization in BMT recipients was also reported for other vaccines, such as Pseudomonas, rubella, mumps, and measles. 10,12 Over the last 10 years, adoptive transfer of humoral and cell-mediated immunity to BMT recipients through vaccination of bone marrow donors has been suggested as a means of protecting immunocompromised patients against bacterial and viral infections.…”
mentioning
confidence: 90%
“…3,6 Attempts at active immunization against HBV in the immediate pre-and post-BMT period were unsuccessful, probably due to inefficient T cell-dependent B cell responses, which may last for about a year following BMT. 10,11 Failure of effective immunization in BMT recipients was also reported for other vaccines, such as Pseudomonas, rubella, mumps, and measles. 10,12 Over the last 10 years, adoptive transfer of humoral and cell-mediated immunity to BMT recipients through vaccination of bone marrow donors has been suggested as a means of protecting immunocompromised patients against bacterial and viral infections.…”
mentioning
confidence: 90%
“…The enhancement of anti-HBV immunity in HBsAg negative recipients is important as anti-HBs positivity has been shown to confer protection against HBV after receiving HBsAg positive marrow (5,8,9). The use of this prophylactic anti-HBV therapy decreased the frequency of HBV-related hepatitis in HBsAg negative recipients from 45.5% to 0%.…”
Section: Discussionmentioning
confidence: 99%
“…Despite the intensive myeloablation and immuno-suppressive effects of allogeneic HSCT, the protective effect of anti-HBV immunity seems to be preserved in some of the hepatitis B surface antibody (anti-HBs) positive recipients (5,9). The persistence of anti-HBV activity in these recipients after transplantation may be due to residual recipient lymphocytes that have survived the intensive preconditioning regime.…”
Section: Introductionmentioning
confidence: 99%
“…[3]. Active immunization against HBV in the pre-and immediate post-BMT period was found to be ineffective, probably due to the absence of T cell-dependent B cell responses, which lasts for approximately I year following BMT [5].…”
Section: Introductionmentioning
confidence: 99%